Review
. 2007 Dec; 18 Suppl 8:viii26-35.
doi: 10.1093/annonc/mdm263.

Safety profiles of tamoxifen and the aromatase inhibitors in adjuvant therapy of hormone-responsive early breast cancer

E A Perez 1 
Affiliations
  • PMID: 17890211
  •     33 citations

Abstract

Adjuvant endocrine therapy plays an important role in the management of hormone-receptor-positive early breast cancer, and has increased life expectancy for millions of women. Many patients receive adjuvant treatment for at least 5 years following tumor resection, hence good long-term safety is important for endocrine agents to gain widespread acceptance. Tamoxifen has been used as adjuvant therapy for early breast cancer for many years, and safety data have been well documented, but a poor risk:benefit profile limits treatment duration to 5 years. Increased efficacy over tamoxifen and good tolerability have recently made the third-generation aromatase inhibitors (AIs) the first-choice agents for adjuvant endocrine therapy; however, it is currently not known whether AI therapy, like tamoxifen, will be limited to 5 years. Many side effects of endocrine therapy, such as hot flushes and mood disturbances, are related to estrogen deprivation and are common to tamoxifen and AIs, reflecting the mechanism of action of these drugs. In addition, tamoxifen has estrogenic effects that are beneficial in some tissues: tamoxifen lowers serum cholesterol levels and protects against bone loss and cardiovascular disease, but is also associated with potentially life-threatening side effects, such as endometrial cancer and thromboembolic disease. As AIs lack estrogenic activity, they are not associated with these serious adverse events. Clinical trials comparing AIs with tamoxifen in the adjuvant setting have shown that AIs are well tolerated and are associated with a lower incidence of gynecological symptoms and hot flushes than tamoxifen. However, AIs are associated with musculoskeletal side effects, such as arthralgia, myalgia and bone loss, but these events are preventable or manageable. The effects of AIs on lipid metabolism and the cardiovascular system are still debatable, but placebo-controlled trials provide no evidence to suggest that AIs adversely affect these systems. Furthermore, the AIs allow women to maintain a good quality of life, comparable with women receiving tamoxifen or placebo, and are a cost-effective therapeutic option. Ongoing trials will provide more information regarding the long-term effects of AI therapy and will provide comparative data on the efficacy and safety of the different AIs, thereby helping to determine the optimal treatment strategy for these highly effective and well-tolerated drugs.

Characterization of the weak estrogen receptor alpha agonistic activity of exemestane.
Selma Masri, Ki Lui, +4 authors, Shiuan Chen.
Breast Cancer Res Treat, 2008 Aug 05; 116(3). PMID: 18677558    Free PMC article.
A radiation-derived gene expression signature predicts clinical outcome for breast cancer patients.
Brian D Piening, Pei Wang, Aravind Subramanian, Amanda G Paulovich.
Radiat Res, 2009 Mar 10; 171(2). PMID: 19267539    Free PMC article.
Exemestane: a review of its use in postmenopausal women with breast cancer.
Emma D Deeks, Lesley J Scott.
Drugs, 2009 May 16; 69(7). PMID: 19441873
Review.
Potential of selective estrogen receptor modulators as treatments and preventives of breast cancer.
Jing Peng, Surojeet Sengupta, V Craig Jordan.
Anticancer Agents Med Chem, 2009 Jun 13; 9(5). PMID: 19519291    Free PMC article.
Review.
CYP2D6 and tamoxifen: DNA matters in breast cancer.
Janelle M Hoskins, Lisa A Carey, Howard L McLeod.
Nat Rev Cancer, 2009 Jul 25; 9(8). PMID: 19629072
Highly Cited. Review.
Molecular characterization of aromatase inhibitor-resistant, tamoxifen-resistant and LTEDaro cell lines.
Selma Masri, Sheryl Phung, Xin Wang, Shiuan Chen.
J Steroid Biochem Mol Biol, 2009 Nov 10; 118(4-5). PMID: 19897035    Free PMC article.
Minimizing early relapse and maximizing treatment outcomes in hormone-sensitive postmenopausal breast cancer: efficacy review of AI trials.
Christos J Markopoulos.
Cancer Metastasis Rev, 2010 Sep 11; 29(4). PMID: 20830503    Free PMC article.
Review.
Optimal adjuvant hormonal therapy in postmenopausal women with hormone-receptor-positive early breast cancer: have we answered the question?
Alfonso Sánchez-Muñoz, Nuria Ribelles, Emilio Alba.
Clin Transl Oncol, 2010 Sep 21; 12(9). PMID: 20851802
Review.
High prevalence of low vitamin D and musculoskeletal complaints in women with breast cancer.
Nicola Napoli, Swapna Vattikuti, +7 authors, Reina Armamento-Villareal.
Breast J, 2010 Nov 13; 16(6). PMID: 21070438    Free PMC article.
Aromatase inhibitor strategies in metastatic breast cancer.
Heather L McArthur, Patrick G Morris.
Int J Womens Health, 2010 Nov 13; 1. PMID: 21072276    Free PMC article.
Putting the cardiovascular safety of aromatase inhibitors in patients with early breast cancer into perspective: a systematic review of the literature.
Muhammad Younus, Michelle Kissner, Lester Reich, Nicola Wallis.
Drug Saf, 2011 Nov 15; 34(12). PMID: 22077502
Systematic Review.
Guidance for the prevention of bone loss and fractures in postmenopausal women treated with aromatase inhibitors for breast cancer: an ESCEO position paper.
R Rizzoli, J J Body, +5 authors, European Society for Clinical and Economical aspects of Osteoporosis and Osteoarthritis (ESCEO).
Osteoporos Int, 2012 Jan 25; 23(11). PMID: 22270857
Aromatase inhibitors and mood disturbances.
Xiomara Rocha-Cadman, Mary Jane Massie, Katherine Du Hamel.
Palliat Support Care, 2012 Jun 09; 10(3). PMID: 22677000    Free PMC article.
Breast cancer chemoprevention: old and new approaches.
Massimiliano Cazzaniga, Bernardo Bonanni.
J Biomed Biotechnol, 2012 Aug 02; 2012. PMID: 22851887    Free PMC article.
Review.
Effectiveness of aromatase inhibitors and tamoxifen in reducing subsequent breast cancer.
Reina Haque, Syed A Ahmed, +5 authors, Joanne E Schottinger.
Cancer Med, 2013 Jan 24; 1(3). PMID: 23342281    Free PMC article.
The predictive impact of body mass index on the efficacy of extended adjuvant endocrine treatment with anastrozole in postmenopausal patients with breast cancer: an analysis of the randomised ABCSG-6a trial.
M Gnant, G Pfeiler, +12 authors, R Jakesz.
Br J Cancer, 2013 Jul 23; 109(3). PMID: 23868011    Free PMC article.
Aromatase inhibitor-associated bone loss and its management with bisphosphonates in patients with breast cancer.
M Bauer, J Bryce, P Hadji.
Breast Cancer (Dove Med Press), 2012 Jan 01; 4. PMID: 24367197    Free PMC article.
Review.
Tamoxifen in breast cancer ipse dixit in uterine malignant mixed Müllerian tumor and sarcoma-A report of 8 cases and review of the literature.
Ana Luisa Cardoso Vasconcelos, Beatriz Nunes, +4 authors, Isabel Monteiro Grillo.
Rep Pract Oncol Radiother, 2014 Jan 15; 18(5). PMID: 24416561    Free PMC article.
Review.
Sex-dependent influence of endogenous estrogen in pulmonary hypertension.
Kirsty M Mair, Audrey F Wright, +8 authors, Margaret R MacLean.
Am J Respir Crit Care Med, 2014 Jun 24; 190(4). PMID: 24956156    Free PMC article.
Effects of modified Shu-Gan-Liang-Xue decoction combined with anastrozole on osteoblastic proliferation and differentiation of MC3T3-E1 cells.
Fei Zhou, Shuyan Han, +2 authors, Pingping Li.
Mol Med Rep, 2014 Nov 19; 11(3). PMID: 25405542    Free PMC article.
Bone Health in Patients with Breast Cancer: Recommendations from an Evidence-Based Canadian Guideline.
Alexander H G Paterson, Melissa A Shea-Budgell.
J Clin Med, 2013 Jan 01; 2(4). PMID: 26237149    Free PMC article.
Review.
CSC-3436 switched tamoxifen-induced autophagy to apoptosis through the inhibition of AMPK/mTOR pathway.
Sheng-Tang Wu, Guang-Huan Sun, +4 authors, Tzong-Der Way.
J Biomed Sci, 2016 Aug 17; 23(1). PMID: 27526942    Free PMC article.
The Working Memory and Dorsolateral Prefrontal-Hippocampal Functional Connectivity Changes in Long-Term Survival Breast Cancer Patients Treated with Tamoxifen.
Xingui Chen, Xiaoxuan He, +9 authors, Kai Wang.
Int J Neuropsychopharmacol, 2017 Feb 09; 20(5). PMID: 28177081    Free PMC article.
Endocrine Therapy Initiation and Medical Oncologist Utilization Among Women Diagnosed with Ductal Carcinoma in Situ.
Chelsea Anderson, Anne Marie Meyer, +3 authors, Hazel B Nichols.
Oncologist, 2017 Apr 15; 22(5). PMID: 28408621    Free PMC article.
Tamoxifen Pharmacovigilance: Implications for Safe Use in the Future.
Demetra Antimisiaris, Ki-Hwan Gabriel Bae, Laura Morton, Zahara Gully.
Consult Pharm, 2017 Sep 01; 32(9). PMID: 28855012    Free PMC article.
Prognostic value of PAM50 and risk of recurrence score in patients with early-stage breast cancer with long-term follow-up.
Hege O Ohnstad, Elin Borgen, +11 authors, Bjørn Naume.
Breast Cancer Res, 2017 Nov 16; 19(1). PMID: 29137653    Free PMC article.
Breast Cancer in Nepal: Current status and future directions.
Mohan Giri, Mamata Giri, +2 authors, Bijay Pariyar.
Biomed Rep, 2018 Mar 16; 8(4). PMID: 29541453    Free PMC article.
Folate Receptor Alpha Peptide Vaccine Generates Immunity in Breast and Ovarian Cancer Patients.
Kimberly R Kalli, Matthew S Block, +11 authors, Keith L Knutson.
Clin Cancer Res, 2018 Mar 17; 24(13). PMID: 29545464    Free PMC article.
Current Status of Extended Adjuvant Endocrine Therapy in Early Stage Breast Cancer.
Irene E G van Hellemond, Sandra M E Geurts, Vivianne C G Tjan-Heijnen.
Curr Treat Options Oncol, 2018 Apr 29; 19(5). PMID: 29704066    Free PMC article.
Review.
Selective Estrogen Receptor Modulators Enhance CNS Remyelination Independent of Estrogen Receptors.
Kelsey A Rankin, Feng Mei, +8 authors, Riley Bove.
J Neurosci, 2019 Jan 31; 39(12). PMID: 30696729    Free PMC article.
Risk of fatty liver after long-term use of tamoxifen in patients with breast cancer.
Jeong-Ju Yoo, Yong Seok Lim, +7 authors, Young Seok Kim.
PLoS One, 2020 Jul 31; 15(7). PMID: 32730287    Free PMC article.
Long-Term Use of Tamoxifen Is Associated With a Decreased Subsequent Meningioma Risk in Patients With Breast Cancer: A Nationwide Population-Based Cohort Study.
Li-Min Sun, Cheng-Li Lin, +3 authors, Chia-Hung Kao.
Front Pharmacol, 2019 Jun 30; 10. PMID: 31249531    Free PMC article.
Effects of tamoxifen and aromatase inhibitors on the risk of acute coronary syndrome in elderly breast cancer patients: An analysis of nationwide data.
Sung Hyouk Choi, Kyoung-Eun Kim, +8 authors, Hyeong-Gon Moon.
Breast, 2020 Sep 06; 54. PMID: 32890789    Free PMC article.